How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients

Background: The literature suggests that medical oncologists differ on how they use the Oncotype DX (ODX) genomic assay for making decisions about systemic therapy in breast cancer patients. Given the emergence of data supporting the use of genomic profiling for the prognosis and predicting benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Xiaofu, Dent, Susan, Paquet, Lise, Zhang, Tinghua, Tesolin, Daniel, Graham, Nadine, Aseyev, Olexiy, Song, Xinni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985759/
https://www.ncbi.nlm.nih.gov/pubmed/33557029
http://dx.doi.org/10.3390/curroncol28010077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985759/
https://www.ncbi.nlm.nih.gov/pubmed/33557029
http://dx.doi.org/10.3390/curroncol28010077

Ejemplares similares